Comment on basal insulin plus bolus insulin or better plus GLP1-RA?

被引：0
|
作者：
Ritzel, Robert A. [1 ,2 ]
机构：
[1] Klin Bogenhausen, Chefarzt Endokrinol Diabetol & Angiol, Munich, Germany
[2] Klin Schwabing, Munich, Germany
来源：
DIABETOLOGIE UND STOFFWECHSEL | 2024年 / 19卷 / 01期
关键词：
D O I：
10.1055/a-2167-7456
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：30 / 31
页数：2
相关论文
共 50 条
  • [1] Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial
    Giugliano, Dario
    Longo, Miriam
    Caruso, Paola
    Di Fraia, Rosa
    Scappaticcio, Lorenzo
    Gicchino, Maurizio
    Petrizzo, Michela
    Bellastella, Giuseppe
    Maiorino, Maria Ida
    Esposito, Katherine
    DIABETES CARE, 2021, 44 (06) : 1353 - 1360
  • [2] Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA1c in T2DM
    Boggild, Miranda K.
    Cheung, Angela M.
    ANNALS OF INTERNAL MEDICINE, 2021, 174 (09) : JC106 - JC106
  • [3] GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen
    Davies, Marie L.
    Pham, David Q.
    Drab, Scott R.
    PHARMACOTHERAPY, 2016, 36 (08): : 893 - 905
  • [4] USE OF BASAL INSULIN-GLP1 COMBINATION FOR THERAPEUTIC SIMPLIFICATION IN TYPE 2 DIABETIC PATIENTS WITH A BASAL-BOLUS OR BASAL PLUS SCHEME
    Jaramillo-Nieto, A.
    Gomez Hernandez, I.
    Tique, C.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A180 - A180
  • [5] The Mobile Insulin Titration Intervention to Transition from Basal Insulin to a GLP1-RA (MITI-GLP1)-Using Daily SMS Text Messages and Weekly Phone Calls to Transition Primary Care Patients with Well-Controlled Type 2 Diabetes Mellitus from Basal Insulin to a GLP1-RA at Bellevue Hospital
    Levy, Natalie
    Nerlino, Katie
    Sonubi, Olubunmi
    Bongalos, Sherlane
    Dasilva, Alex
    Uzor, Chinye
    Liang, Yingjie
    DIABETES, 2024, 73
  • [6] GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis
    Castellana, Marco
    Cignarelli, Angelo
    Brescia, Francesco
    Laviola, Luigi
    Giorgino, Francesco
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2019, 35 (01)
  • [7] COST-EFFECTIVENESS ANALYSIS OF SWITCHING FROM BASAL INSULIN plus ORAL ANTIDIABETICS-GLP1-RA TO IDEGLIRA IN BRAZIL
    de Almeida, V
    Leonart, L. P.
    Tonin, F.
    Izar Helfenstein Fonseca, M.
    Miyamoto Fortes, E.
    Melo, T.
    Pititto, L.
    Gaspar, A.
    Krakauer, M.
    VALUE IN HEALTH, 2022, 25 (07) : S391 - S391
  • [8] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
    Valentine, WJ
    Wittrup-Jensen, KU
    Palmer, AJ
    Roze, S
    DIABETES, 2005, 54 : A609 - A609
  • [9] Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin
    Bolli, Geremia B.
    Porcellati, Francesca
    Meier, Juris J.
    DIABETES CARE, 2020, 43 (10) : 2333 - 2335
  • [10] Cost-effectiveness analysis of basal-bolus therapy of type 1 diabetes using insulin detemir plus insulin aspart versus NPH plus insulin aspart regimens
    Valentine, WJ
    Wittrup-Jensen, KU
    Häuser, C
    Roze, S
    DIABETOLOGIA, 2005, 48 : A334 - A334
12345